GDA 301
Alternative Names: GDA-301Latest Information Update: 17 Apr 2023
At a glance
- Originator Gamida-Cell
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 17 Apr 2023 Discontinued - Preclinical for Haematological malignancies in Israel (Parenteral) (Gamida-Cell pipeline, April 2023)
- 17 Apr 2023 Discontinued - Preclinical for Solid tumours in Israel (Parenteral) (Gamida-Cell pipeline, April 2023)
- 27 Mar 2023 Gamida Cell plans to discontinue the development of GDA 301